Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX07 Cabozantinib
D10062 Cabozantinib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG01670 Cabozantinib
D10062 Cabozantinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
VEGFR family
VEGFR2 (KDR)
D10062 Cabozantinib (USAN)
MET family
MET
D10062 Cabozantinib (USAN)
AXL family
AXL
D10062 Cabozantinib (USAN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10062
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG01670 Cabozantinib